healthcare

healthcare Articles

Global Blood Therapeutics shares jumped on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta (voxelotor) tablets for the...
Medicines Co shares shot up on Monday after it was reported that Novartis will be acquiring the firm. The transaction was unanimously approved by the boards of directors of both companies.
Aquestive Therapeutics shares jumped on Monday after the firm announced that its treatment of amyotrophic lateral sclerosis (ALS), Exservan, received early-action approval from the U.S. Food and Drug...
Iovance Bio announced results from a subgroup analysis of metastatic melanoma patients in its Phase 2 study of lifileucel.
ProQR Therapeutics shares jumped early on Thursday after the firm announced that it received an approval from the FDA for its autosomal dominant retinitis pigmentosa drug.
Aravive shares skyrocketed on Wednesday after the firm announced early-stage data for its ovarian cancer treatment.
Kiniksa Pharma shares jumped on Wednesday after the firm announced that the FDA granted Breakthrough Therapy designation for rilonacept for the treatment of recurrent pericarditis.
Karuna Therapeutics shares skyrocketed on Monday after the firm announced mid-stage results from its schizophrenia treatment. Now shares are on the move again after Karuna said that it would be...
Myovant Sciences shares more than doubled on Tuesday after the firm announced results from its Phase 3 Hero study of relugolix for prostate cancer.
Medicines shares shot up on Tuesday after it was reported that Novartis might be eyeing this company as its newest acquisition.
Canada-based pot supplier Aurora Cannabis posted better-than-expected profits but revenues plunged and growth prospects have dimmed.
Tilray released its third quarter financial results after the closing bell on Tuesday. The company said that it had a net loss of $0.50 per share and $51.1 million in revenue, compared with consensus...
Tilray is scheduled to release its third-quarter financial results after the markets close on Tuesday. Analysts on average expect another net loss.
Solid Bio shares were absolutely crushed on Tuesday after the firm announced that the FDA has placed its Ignite DMD Phase 1/2 study of SGT-001 on hold.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The October 31 short interest data has been compared with the previous report, and short interest in...